Likewise, several recent phase-2b clinical trials have shown the remarkable effects of long-acting FGF21 analogs in decreasing liver fat content, inflammation, fibrosis, and dyslipidemia in individuals with obesity who have biopsy-confirmed NASH, accompanied by obvious elevations in plasma adiponectin levels (Abdelmalek et al, 2021; Bhatt et al, 2023; Loomba et al, 2023). The gene discussed is FGF21; the disease is Obesity.